DelSiTech Ltd., a company specializing in clinical-stage drug delivery and development, has announced a global license and development agreement with Tolmar International Ltd., a fully-integrated pharmaceutical company.

Krystal Biotech, Inc, a biotechnology company, announced today that the U.S. Food and Drug Administration has granted Fast Track Designation for inhaled KB707. This designation aims to expedite the development

HTuO Biosciences, a biotech company specializing in molecular simulation for drug discovery, has recently joined Johnson & Johnson Innovation - JLABS as a resident virtual company.

Corvus Pharmaceuticals, Inc, a biopharmaceutical company focusing on clinical-stage developments, announced new findings on soquelitinib, its leading ITK inhibitor program

Disc Medicine, Inc, a company focused on developing treatments for serious hematologic diseases, announced that the United States Food and Drug Administration has granted Orphan Drug Designation to DISC-3405 for treating polycythemia vera patients.

Nascent Biotech, Inc. recently announced a research collaboration agreement with Manhattan BioSolutions, Inc. The collaboration aims to investigate antibody-drug conjugates utilizing Nascent’s lead clinical candidate

Calibr-Skaggs Institute for Innovative Medicines, the nonprofit arm of Scripps Research focusing on drug development, has revealed an expansion in its collaboration with AbbVie. This extension aims to further investigate Calibr-Skaggs' switchable CAR-T

Triumvira Immunologics, a clinical-stage biotech company focusing on developing innovative autologous and allogeneic T cell therapies for solid tumors, has announced the initiation of dosing for the first patient in its TACTIC-3 trial

Vanda Pharmaceuticals Inc. announced today, it received notification from the U.S. Food and Drug Administration regarding its supplemental New Drug Application for HETLIOZ® aimed at treating insomnia characterized by difficulties with sleep initiation. The FDA

Regeneron Pharmaceuticals, Inc. recently announced that the European Medicines Agency has accepted the Marketing Authorization Application for linvoseltamab, a bispecific antibody